Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Celltrion (068270 KP)
Watchlist
21
Analysis
Health Care
•
South Korea
Celltrion, Inc. produces and sells biosimilar products, as well as consignment processing services for other businesses.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
22 Apr 2016 10:10
How Korea National Pension Fund Is Exerting Pressure on Companies to Raise Dividends
Korea National Pension Fund (KNPF), the third largest pension fund in the world, has been exerting more pressure on Korean companies to raise their...
Douglas Kim
Follow
214 Views
Share
bearish
•
Celltrion Inc
•
09 Apr 2016 05:22
U.S. Remsima Expectations Too Optimistic
USFDA approved Celltrion’s Remsima, a biosimilar for JNJ’s Remicade, for use in treating rheumatoid arthritis, ulcerative colitis, Crohn’s, and...
Kemp Dolliver, CFA
207 Views
Share
bearish
•
Celltrion Inc
•
26 Mar 2016 21:33
Serious Questions to Consider
Our initial post on Celltrion focused on the fundamental risk of whether the company could meet the market's high expectations for its first...
Kemp Dolliver, CFA
203 Views
Share
bullish
•
Thematic (Sector/Industry)
•
29 Feb 2016 14:39
Share Buybacks in Korea - Top 9 Insights
In this report, we highlight 39 companies that have announced share buybacks in the past three months (Dec 2015 - Feb 2016) in Korea. We provide...
Douglas Kim
Follow
260 Views
Share
bullish
•
Thematic (Sector/Industry)
•
16 Feb 2016 00:59
2016 Major IPOs Pipeline in Korea - Part II
In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...
Douglas Kim
Follow
230 Views
Share
First
Previous
91
92
93
94
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x